Healthcare / Drug Manufacturers - Specialty & GenericTel Aviv
$1397.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-3.8M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12M
P/E
N/A
•EV/EBITDA
N/A
•ROE
120.4%
↑Gross Margin
9.7%
↓Debt/Equity
-0.90
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-43.1%
FCF CAGR
—
FCF margin
22.1%
FCF / Net income
-0.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.1M · net income $-15.9M · FCF $2.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.1M | $9.1M | $35.0M | $44.2M | $49.3M |
| Net Income | $-15.9M | $-15.9M | $-40.1M | $-88.9M | $-48.2M |
| EBITDA | $-2.2M | $-2.2M | $-8.6M | $-33.0M | $4.8M |
| EPS | — | — | -47.90 | -141.00 | -94.81 |
| Gross Margin | 9.7% | 9.7% | -3.5% | -4.0% | 4.9% |
| Operating Margin | -105.4% | -105.4% | -42.0% | -64.4% | -54.1% |
| Net Margin | -174.2% | -174.2% | -114.7% | -201.0% | -97.8% |
| Balance Sheet | |||||
| Debt/Equity | -0.90 | -0.90 | 6.54 | 0.49 | 0.16 |
| Current Ratio | 0.06 | 0.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.0M | $2.0M | $-3.8M | $-4.1M | $-30.1M |
| Returns | |||||
| ROE | 120.4% | 120.4% | -1615.0% | -217.5% | -40.3% |
| Valuation | |||||
| EV/EBITDA | — | — | — | — | 1235.86 |
| P/B | — | — | 1301.59 | 50.57 | 49.78 |
| Growth & Yield | |||||
| Revenue Growth | -74.0% | -74.0% | -21.0% | -10.3% | — |
| EPS Growth | — | — | 66.0% | -48.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-47.90 → n/d
Residual
-61.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.